3 news items
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
APLS
10 Jun 24
approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
APLS
7 May 24
. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
APLS
4 Apr 24
by such forward-looking statements as a result of various important factors, including whether the benefit/risk profile of SYFOVRE following
- Prev
- 1
- Next